Anfibatide Phase Ib-IIa Clinical Trial

Non-ST Segment Elevation Myocardial Infarction Clinical Trial

Official title:
A Multi-center, Randomized, Double-blind, Multi-dose Group, Parallel Group and Placebo Controlled Phase Ib-IIa Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin for Injection for the Treatment of Patients With Non-ST Segment Elevation Myocardial Infarction (NSTEMI).

Status Completed

Clinical Trial Summary

Investigate the safety and efficacy of Anfibatide in non-ST segment myocardial infarction patients

Clinical Trial Description

1. This study is a phase Ib-IIa exploratory study to observe the safety of Antiplatelet Thrombolysin for Injection for the treatment of non-ST segment myocardial infarction (NSTEMI) patients and preliminarily evaluate the efficacy of different doses, providing the theoretical basis of the phase II and III clinical study protocol. 2. To investigate the pharmacokinetics of different doses. ;

Study Design

Related Conditions & MeSH terms

Infarction
Myocardial Infarction
Non-ST Segment Elevation Myocardial Infarction

Clinical Trial Details

NCT number	NCT01585259
Study type	Interventional
Source	Lee's Pharmaceutical Limited
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	July 2012
Completion date	July 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02026219` - Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction	Phase 4
Completed	`NCT01293097` - Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI	Phase 4
Completed	`NCT02601157` - Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial	Phase 4
Completed	`NCT03565978` - Cardiac Care Solution for Coronary Disease Follow up	N/A